scispace - formally typeset
Search or ask a question
Institution

Hebron University

EducationHebron, Palestinian Territory
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
Abstract: Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1–5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1–10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23–67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63–89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.

55 citations

Journal ArticleDOI
TL;DR: No learning effect was found in patients with NPH on any of the neuropsychological or motor tests performed over 4 consecutive days, and this strategy can therefore be used in both the diagnosis and evaluation of surgical outcomes.
Abstract: Object The test-retest method is commonly used in the management of patients with normal-pressure hydrocephalus (NPH). One of the most widely used techniques in the diagnosis of this condition is evaluation of the patient's response to CSF evacuation by lumbar puncture (a so-called tap test or spinal tap). However, interpretation of improved results in subsequent evaluations is controversial because higher scores could reflect a real change in specific abilities or could be simply the result of a learning effect. Methods To determine the effect of testing-retesting in patients with NPH, the authors analyzed changes documented on 5 neuropsychological tests (the Toulouse-Pieron, Trail Making Test A, Grooved Pegboard, Word Fluency, and Bingley Memory tests) and several motor ability scales (motor performance test, length of step, and walking speed tests) in a series of 32 patients with NPH who underwent the same battery on 4 consecutive days. The same tests were also applied in 30 healthy volunteers. In both...

55 citations

Journal ArticleDOI
TL;DR: There has been a significant improvement in survival of patients diagnosed with IBC over a two-decade time span in this large population-based study, suggesting that therapeutic strategies researched and evolved in the context of non-IBC have also had a positive impact in women with I BC.

55 citations

Journal ArticleDOI
TL;DR: Patients with stage IIIA (N2 or T4N0) are potentially curable but median overall survival is only around 15 months and complete pathologic response with conventional chemotherapy (C...
Abstract: 8509Background: Patients with stage IIIA (N2 or T4N0) are potentially curable but median overall survival is only around 15 months and complete pathologic response with conventional chemotherapy (C...

54 citations


Authors

Showing all 2723 results

NameH-indexPapersCitations
José Baselga156707122498
M. I. Martínez134125179885
Josep Tabernero11180368982
Jordi Rello10369435994
Xavier Montalban9576252842
James M. Downey9138129506
Enriqueta Felip8362253364
Joaquim Bellmunt8266041472
Joan Montaner8048922413
Marc Miravitlles7665125671
David H. Salat7524136779
Eduard Gratacós7553120178
Alex Rovira7435619586
Ramon Bataller7228319316
Maria Buti7149326596
Network Information
Related Institutions (5)
Memorial Sloan Kettering Cancer Center
65.3K papers, 4.4M citations

89% related

University of Texas MD Anderson Cancer Center
92.5K papers, 4.7M citations

89% related

VU University Medical Center
22.9K papers, 1.1M citations

88% related

Netherlands Cancer Institute
17.2K papers, 1.1M citations

88% related

Mayo Clinic
169.5K papers, 8.1M citations

87% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20232
202212
2021568
2020545
2019483
2018385